Plain-English translation of NCT07555431 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether dolutegravir, a medication that works by blocking a viral enzyme, can treat HTLV-1 infection. Some people will take dolutegravir alone, while others will take it combined with tenofovir, another antiviral drug. The study will measure whether these treatments reduce the virus and improve symptoms over 48 weeks.
HTLV-1 is a serious, neglected infection that can cause severe nerve damage and blood cancers, but there is currently no proven antiviral treatment available. This trial aims to find out whether this medication can help patients by lowering the virus in their body and preventing disease progression.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take either one medication or two medications by mouth daily for 48 weeks. Throughout the study, you will have regular clinic visits to have blood tests, physical exams, and discussions about your symptoms and how you are feeling. The research team will track whether the virus decreases in your blood and whether your nerve or other symptoms improve.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
Brazil
Phase
Testing effectiveness
Sponsor
Carlos Brites
Enrollment target
~146 participants
Started
May 2026
Primary completion
May 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Carlos Brites, MD, PhD
Hospital Universitário Professor Edgard Santos, Federal University of Bahia
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.